People: ACADIA Pharmaceuticals Inc (ACAD.W)

Summary

Name	Age	Since	Current Position
Leslie Iversen	74	2000	Independent Chairman of the Board
Uli Hacksell	61	2009	President, Chief Executive Officer, Director
Thomas Aasen	51	2009	Chief Financial Officer, Executive Vice President, Treasurer, Chief Business Officer
Roger Mills	54	2006	Executive Vice President - Development
Glenn Baity	42	2004	Vice President, General Counsel, Secretary
Stephen Biggar		2013	Director
Michael Borer	53	2005	Independent Director
Laura Brege	54	2008	Independent Director
Mary Gray	59	2005	Independent Director
Lester Kaplan	61	1997	Independent Director
Torsten Rasmussen	68	1998	Independent Director
William Wells	51	2012	Independent Director

» Insider Trading

Biographies

Name	Description
Leslie Iversen	Dr. Leslie L. Iversen, Ph.D., is Independent Chairman of the Board of ACADIA Pharmaceuticals, Inc., since December 2000. He has served as a Director since 1998. He also was a founding member of Scientific Advisory Board. Dr. Iversen is currently a Professor of Pharmacology at University of Oxford, England, where he has taught since 1995. He was previously a Professor of Pharmacology at King’s College, London where he was Director of the Wolfson Centre for Age Related Diseases from 1999 until 2004. Dr. Iversen is internationally recognized for his fundamental contributions to the understanding of neurotransmission. Dr. Iversen served as Vice President of Neuroscience Research, Merck Research Laboratories and Director of the Neuroscience Research Center of Merck Research Laboratories in the UK. He was formerly Director of the Medical Research Council Neurochemical Pharmacology Unit in Cambridge. More recently, Dr. Iversen founded and serves as a director of Panos Therapeutics Ltd. The NCG Committee believes that Dr. Iversen’s long tenure as Board Chairman positions him to contribute to the Board his knowledge of the Company and to provide Board continuity. Dr. Iversen is the recipient of numerous awards, including Fellow of the Royal Society of London and Foreign Associate Member of the National Academy of Sciences in the United States. Dr. Iversen received a Ph.D. and B.A. from the University of Cambridge.
Uli Hacksell	Dr. Uli Hacksell Ph.D., is President, Chief Executive Officer, Director of ACADIA Phamaceuticals Inc. He has served as Chief Executive Officer since September 2000 and as a director of company since October 2000. From February 1999 to September 2000, he served as Executive Vice President of Drug Discovery. From August 1991 to February 1999, Dr. Hacksell held various senior executive positions at Astra, a pharmaceutical company, including Vice President of Drug Discovery and Technology as well as President of Astra Draco, one of Astra’s research and development subsidiaries, where he directed an organization of more than 1,100 employees. From August 1991 to May 1994, he served as Vice President of CNS Preclinical R&D at Astra Arcus, another subsidiary. Earlier in his career, Dr. Hacksell held the positions of Professor of Organic Chemistry and Department Chairman at Uppsala University in Sweden and also served as Chairman and Vice Chairman of the European Federation of Medicinal Chemistry. He currently serves on the board of directors of SLS Invest AB. The NCG Committee believes that Dr. Hacksell’s experience with the Company, which are a consequence of his long tenure as Chief Executive Officer and director, bring necessary historic knowledge and continuity to the Board. Dr. Hacksell received a Master of Pharmacy and a Ph.D. in Medicinal Chemistry from Uppsala University.
Thomas Aasen	Mr. Thomas H. Aasen is Chief Financial Officer, Executive Vice President, Treasurer, Chief Business Officer of ACADIA Pharmaceuticals, Inc. He has been with the Company since April 1998. Prior to joining, Mr. Aasen held financial management positions at several publically traded life sciences companies, including Senior Director of Finance and Administration at Axys Pharmaceuticals, formerly called Sequana Therapeutics, Director of Finance at Genta, Inc., and Director of Accounting at Gen-Probe, Inc. Earlier in his career, Mr. Aasen held various positions in public accounting at KPMG Peat Marwick, including Audit Manager. He has 29 years of professional finance and accounting experience focused primarily on the life sciences industry. Mr. Aasen received a B.S. degree with honors from San Diego State University and is a licensed certified public accountant (inactive status) in the State of California.
Roger Mills	Dr. Roger M. Mills, M.D., is Executive Vice President, Development of ACADIA Pharmaceuticals, Inc., since June 5, 2006. Prior to joining the Company, Dr. Mills held the position of Vice President, Development at Pfizer Global R&D, a division of Pfizer Inc., which is a global pharmaceutical company, for a five-year period. In this capacity, he was responsible for the management and direction of drug development activities at the Pfizer campus in La Jolla, California, and played a key role in the development of Sutent®, a new multikinase inhibitor for patients with advanced renal cell carcinoma and gastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Mills held senior clinical management positions at Gilead Sciences, where he served as project leader in the development of Tamiflu®, a treatment for influenza, and at Abbott Laboratories, where he played an important role in the development of antiviral drugs. Earlier in his career, he held several senior positions at the Wellcome Foundation, including Scientific Advisor for Group Marketing and Therapeutic Area Head, Cardiovascular Marketing. Dr. Mills received his medical degree at the Charing Cross Hospital Medical School in London and his specialized medical training at the Royal College of General Practitioners in London.
Glenn Baity	Mr. Glenn F. Baity is Vice President, General Counsel, Secretary of ACADIA Pharmaceuticals Inc's., since July 2004. From February 2000 until joining, Mr. Baity was a senior associate at Cooley LLP in their San Diego office, working with a variety of public and private companies on transactional matters, including M&A, financings, compensation and equity matters, and corporate governance. From January 1997 to January 2000, Mr. Baity was an associate in the San Francisco office of Brown & Wood LLP (now Sidley Austin LLP) working primarily on public financings for established companies while representing bulge bracket underwriters, such as Goldman Sachs, Merrill Lynch and Morgan Stanley. Mr. Baity received a J.D. degree from the University of California, Los Angeles and received a B.A. from the University of California, Berkeley.
Stephen Biggar	Dr. Stephen R. Biggar, M.D., Ph.D., has been appointed as Director of Acadia Pharmaceuticals Inc. effective January 22, 2013. Dr. Biggar serves as a Partner at Baker Brothers Investments, a fund management company focused on long-term investments in life-sciences companies. From April 2002 to October 2006, he served as a Principal with Baker Brothers Investments which he had joined as an Associate in April 2000. Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester. Dr. Biggar also serves as a director for Synageva BioPharma Corp., a publicly traded biotechnology company.
Michael Borer	Mr. Michael T. Borer is Independent Director of ACADIA Pharmaceuticals, Inc., since September 13, 2005. Mr. Borer served as Chief Executive Officer and President of Xcel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on prescription products that treat disorders of the central nervous system, until the sale of the company to Valeant Pharmaceuticals International in early 2005. Prior to founding Xcel in early 2001, Mr. Borer served as Senior Vice President and Chief Financial Officer of Dura Pharmaceuticals, Inc. and held other management positions there from 1994 through 2000. Prior to Dura, Mr. Borer spent 12 years in public accounting with Deloitte & Touche in its audit services group. He holds a bachelor’s degree in accounting from San Diego State University.
Laura Brege	Ms. Laura A. Brege is Independent Director of ACADIA Pharmaceuticals, Inc., since May 1, 2008. Ms. Brege is Executive Vice President and Chief Operating Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where she is responsible for sales and marketing, medical affairs, legal, and compliance functions. She joined Onyx in June 2006 as Executive Vice President and Chief Business Officer and was promoted to her current position in October 2007. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies, since 1999. Prior to Red Rock, she was the Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. The Nominating and Corporate Governance Committee believes that Ms. Brege’s industry background, including her experience as an officer of public companies in the biotechnology industry, position her to make an effective contribution to the Board and the Audit Committee. In addition, her past financial experience and current knowledge of financing trends are extremely to the Board when considering financing strategies for the Company. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. Ms. Brege also serves on the boards of Angiotech Pharmaceuticals, Inc. and The Ohio University Foundation.
Mary Gray	Dr. Mary Ann Gray, Ph.D., is Independent Director of ACADIA Pharmaceuticals, Inc., since April 27, 2005. Currently, Dr. Gray is President of Gray Strategic Advisors, LLC, a company which she started in 2003 and which provides strategic consulting services to the biotechnology industry. Dr. Gray also serves on the boards of directors of Dyax Corp. and Apthera Inc., a privately held company. During the past five years, Dr. Gray also served on the board of directors for each of GTC Biotherapeutics Inc. and Telik, Inc., each a public company. From 1999 to 2003, Dr. Gray was Senior Analyst and Portfolio Manager for the Federated Kaufmann Fund. Prior to 1999, Dr. Gray led biotechnology equity research groups at Raymond James & Associates, Warburg Dillon Read and Kidder Peabody for an aggregate of nine years. The NCG Committee believes that Dr. Gray’s scientific background, financial industry experience and public board experience make her a contributor to Board discussions. Dr. Gray holds a Ph.D. degree in pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer.
Lester Kaplan	Dr. Lester J. Kaplan, Ph.D., is Independent Director of ACADIA Pharmaceuticals, Inc.. since November 1997. Dr. Kaplan was Executive Vice President and President, Research and Development, at Allergan, Inc. from November 2003 to April 2004. Dr. Kaplan joined Allergan in 1983 and, prior to being appointed to Executive Vice President, was Corporate Vice President, Research and Development and Global BOTOX from June 1998 to November 2003. Dr. Kaplan was elected to Allergan’s board of directors in 1994 and served in that capacity until April 2004. Dr. Kaplan is Executive Chairman of the Board of Aciex Therapeutics Inc., Chairman of the Board of Altheos, Inc., and a member of the Board of The National Neurovision Research Institute. He serves on the Scientific Advisory Board of Bay City Capital. The NCG Committee believes that Dr. Kaplan’s long tenure as a board member and chair of Compensation Committee allows him to contribute his knowledge of the Company and to provide Board and compensation continuity. In addition, the NCG Committee believes that his research and development and venture capital background position him to make an effective contribution to the Board’s evaluation of strategic and financial alternatives. In particular, as the Company undertakes additional clinical trials in Phase II and Phase III for its lead compound, Dr. Kaplan’s prior experience with clinical trials and other development activities provide invaluable insight for the Board. Dr. Kaplan received a M.S. and Ph.D. in organic chemistry from the University of California, Los Angeles.
Torsten Rasmussen	Mr. Torsten Erik Rasmussen is Independent Director of ACADIA Pharmaceuticals, Inc., since April 1998. Mr. Rasmussen has been President and Chief Executive Officer of Morgan Management ApS, a management advisory and consulting company, since 1997. Prior to founding Morgan Management in 1997, Mr. Rasmussen had held the position of Executive Vice President, Operations at the LEGO Group (LEGO A/S) in Denmark since 1981. He currently serves as a board member in the capacity of chairman, deputy chairman or ordinary board member of a number of Danish companies of which the following are quoted on the Danish Stock Exchange: Coloplast A/S, TK Development A/S, Vestas Wind Systems A/S, and A/S Det Oestasiatiske Kompagni. The NCG Committee believes that Mr. Rasmussen’s experience with international business will be to the Board as the Company seeks opportunities outside of North America for its lead compound. In addition, the NCG Committee believes that Mr. Rasmussen’s tenure with the Board, brings historic knowledge and continuity to the Board and the committees on which he sits. Mr. Rasmussen holds an M.B.A. from IMD in Lausanne, Switzerland.
William Wells	Mr. William M. Wells is Independent Director of ACADIA Pharmaceuticals Inc., effective January 27, 2012. Mr. Wells was Chief Executive Officer of Biovail Corporation from May 2008 through the time of its merger with Valeant Pharmaceuticals International, Inc. in September 2010, during which time he led Biovail's strategic transformation into a specialty pharmaceutical company focused on specialty central nervous system markets. Following the merger, Mr. Wells served as Chairman of Valeant until December 2010. He was originally elected to the board of directors of Biovail in June 2005 and later served as Lead Director until his appointment as Chief Executive Officer. Prior to joining Biovail, Mr. Wells held a number of senior executive positions, including Chief Financial Officer of Loblaw Companies Limited, Canada's food distributor and a provider of general merchandise products, drugstore and financial products and services, Chief Financial Officer of Bunge Limited, a U.S. headquartered company engaged in the global agribusiness, fertilizer and food product industries, and financial management positions at McDonald's Corporation in the U.S. and Brazil. Mr. Wells is currently Chairman of the Board of Evizone Ltd., a privately held online communications service firm, and a Trustee and member of the audit committee of the Lakefield College School Foundation. Mr. Wells holds a Master's degree in International Business from the University of South Carolina and a Bachelor's degree in Philosophy and English from the University of Western Ontario.

Basic Compensation

Name	Fiscal Year Total
Leslie Iversen	--
Uli Hacksell	933,353
Thomas Aasen	572,944
Roger Mills	619,762
Glenn Baity	478,082
Stephen Biggar	--
Michael Borer	--
Laura Brege	--
Mary Gray	--
Lester Kaplan	--
Torsten Rasmussen	--
William Wells	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Leslie Iversen	0	0
Uli Hacksell	424,084	3,093,980
Thomas Aasen	199,000	1,533,340
Roger Mills	0	0
Glenn Baity	0	0
Stephen Biggar	0	0
Michael Borer	0	0
Laura Brege	0	0
Mary Gray	0	0
Lester Kaplan	0	0
Torsten Rasmussen	0	0
William Wells	0	0

Insider Trading

Name	Shares Traded	Price
HACKSELL ULI	20,449	$12.34
HACKSELL ULI	20,449	$1.08
HACKSELL ULI	20,449	$0.00
HACKSELL ULI	20,449	$0.00
HACKSELL ULI	19,551	$12.71
HACKSELL ULI	19,551	$1.08
HACKSELL ULI	19,551	$0.00
HACKSELL ULI	19,551	$0.00
BAITY GLENN F	10,000	$1.62
BAITY GLENN F	10,000	$13.15
BAITY GLENN F	10,000	$1.55
BAITY GLENN F	10,000	$12.26
HACKSELL ULI	16,729	$1.08
BAITY GLENN F	20,000	$12.30
HACKSELL ULI	16,729	$0.00
BAITY GLENN F	10,000	$1.55
HACKSELL ULI	16,729	$12.32
HACKSELL ULI	16,729	$0.00
BAITY GLENN F	10,000	$1.55
BAITY GLENN F	20,000	$12.50
BAITY GLENN F	10,000	$1.55
BAITY GLENN F	10,000	$1.55
BAITY GLENN F	10,000	$13.00
BAITY GLENN F	20,000	$12.74
BAITY GLENN F	10,000	$1.55

» Full list on Insider Trading

People: ACADIA Pharmaceuticals Inc (ACAD.W)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: